Does oral acetyl-L-carnitine (ALCAR) raise TMAO, and should that change who takes it?

Yes, oral acetyl-L-carnitine raises TMAO, and for some people that should change the decision to take it. If you have chronic kidney disease, are on dialysis, have established cardiovascular disease, or have heart failure, ALCAR deserves extra caution unless there is a specific medical reason for it. In a healthy person with normal kidney function, the answer is less absolute: the biomarker moves in the wrong direction, but event-level harm from ALCAR itself has not been proven.

What the human ALCAR evidence shows

The most direct evidence is a 2025 human pharmacokinetic study by Krims-Davis and colleagues. Healthy volunteers took oral acetylcarnitine at 0.5 g or 1.5 g, with plasma and urine measured by LC-MS/MS over 48 hours. After 1.5 g ALCAR, median plasma TMAO rose from about 2.2 to about 47.0 micromol/L, peaking near 16 hours. After 0.5 g, median TMAO rose from about 3.2 to about 26.3 micromol/L. Urinary TMAO rose about 10-fold.¹

That is not a small lab wiggle. It crosses the range used in several cardiovascular and kidney observational studies to define higher-risk TMAO groups. The ALCAR study also matters because it addresses the common assumption that acetyl-L-carnitine behaves differently from L-carnitine. The authors reported low intact ALCAR bioavailability and that acetylcarnitine was largely recovered as free carnitine, with roughly 90 percent of the carnitine-class supplement metabolized to TMAO.¹ In plain English: the acetyl group does not rescue ALCAR from the carnitine pathway.

The pathway is biologically coherent. Gut microbes convert carnitine through intermediates such as gamma-butyrobetaine to trimethylamine, then liver flavin monooxygenases oxidize trimethylamine to TMAO. In the Koeth and Tang carnitine work, omnivores produced far more TMAO from an oral carnitine challenge than vegans or vegetarians, and broad-spectrum antibiotics nearly abolished TMAO generation until gut microbiota recovered.2 Later work identified anaerobic gamma-butyrobetaine pathways, including bbu and gbu genes, as important human-gut contributors to trimethylamine generation from carnitine-derived substrates.3, ⁴

Why the outcome evidence is concerning but not final

The strongest honest statement is this: ALCAR clearly worsens a risk-linked biomarker, but no randomized outcomes trial has shown that ALCAR itself causes more heart attacks, strokes, kidney failure, or deaths.

Still, the biomarker is not random. In Tang and colleagues' NEJM study of 4,007 patients undergoing cardiac evaluation, higher plasma TMAO predicted major adverse cardiovascular events over 3 years, with the highest versus lowest quartile associated with substantially higher risk.5 In 720 patients with stable heart failure, higher fasting TMAO predicted 5-year all-cause mortality, including after adjustment for cardiorenal indexes.6 In older adults from the Cardiovascular Health Study, TMAO and related metabolites were positively associated with mortality, with risk strongest among people with lower kidney function.7 A 2024 JASN study also reported that higher TMAO was associated with incident chronic kidney disease and kidney function decline.⁸

Mechanistic data make those associations harder to dismiss. TMAO has been linked in experimental models to macrophage foam-cell formation, scavenger receptor signaling, impaired cholesterol handling, endothelial dysfunction, and platelet hyperreactivity. Wang and colleagues showed that choline, betaine, and TMAO promoted atherosclerosis-related pathways in mice.9 Zhu and colleagues showed that TMAO enhanced platelet responsiveness and thrombosis potential in animal models and human platelet experiments.10 So the popular worry that ALCAR could affect vascular risk is directionally reasonable, but the precise concern is arterial atherosclerosis and clot-proneness, not "hardening veins."

Who should think twice

Kidney function changes the answer most. TMAO is renally cleared, so impaired clearance can turn the same production rate into much higher circulating exposure. Dialysis cohorts have reported median TMAO around 94 micromol/L versus about 3.3 micromol/L in healthy controls.¹¹ In hemodialysis patients, 900 mg per day oral L-carnitine increased both TMA and TMAO over 6 months.12 That does not prove ALCAR is harmful in dialysis, but it makes casual use hard to justify.

Cardiovascular disease and heart failure also change the decision. These are the populations where higher TMAO has repeatedly tracked with worse outcomes.5, 6 If someone already has coronary artery disease, prior stroke, peripheral artery disease, or heart failure, the bar for chronic ALCAR should be higher than "it might help energy."

Microbiome status matters too. Omnivores, especially people with high-TMAO-producing gut microbiomes, generate more TMAO from carnitine than vegans or vegetarians.2 Recent gbu-gene work suggests that fecal gbu abundance, especially gbuB, may identify high producers, rises with L-carnitine supplementation, and falls with a plant-based diet.⁴ Most people do not know their gbu status, so diet pattern is an imperfect but useful clue.

The thing that does not matter as much as people think

The likely confound is the form: "I am taking ALCAR, not L-carnitine." For TMAO, that distinction is not protective. The direct ALCAR pharmacokinetic study found low intact ALCAR bioavailability and substantial conversion into carnitine-class metabolites leading to TMAO.¹

Another confound is inflammation over a short window. In healthy older women taking 1.5 g per day L-carnitine tartrate for 24 weeks, fasting TMAO rose about 10-fold, but CRP, IL-6, TNF-alpha, adhesion molecules, oxidized LDL, and lipid markers did not worsen over that period.13 That is reassuring, but narrow. It does not answer whether years of higher TMAO matter, or whether higher-risk patients respond differently.

The decision today

If you have CKD, are on dialysis, have established cardiovascular disease, or have heart failure, do not take ALCAR casually. Use it only when the expected benefit is concrete and your clinician agrees the tradeoff is reasonable. If you are healthy, have normal kidney function, eat mostly plant-based, and are using a modest dose for a defined reason, the case against ALCAR is weaker. But the supplement should be treated as TMAO-raising, not TMAO-neutral. The practical choice is simple: if the benefit is vague, skip it; if the benefit is specific, use the lowest effective dose and reassess rather than making it a permanent daily habit.